The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.
SGS742 is a GABA(B) receptor antagonist. It is an orally active drug and possesses neurochemical and psychopharmacologic features that suggest it could improve memory and cognition in humans. The primary objective of the SGS742 clinical trial will be to determine the effect of SGS742 on memory and cognition in individuals diagnosed with mild to moderate Alzheimer's disease. The duration of the study is 3 months with 5 clinic visits.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
280
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Phoenix, Arizona, United States
Dedicated Clinical Research
Sun City, Arizona, United States
Northwest NeuroSpecialists, PLLC
Tucson, Arizona, United States
Clinical Trials Incorporated
Little Rock, Arkansas, United States
Margolin Brain Institute
Fresno, California, United States
NervePro Research
Irvine, California, United States
Center for Neurologic Studies
La Jolla, California, United States
Neuro Therapeutics, Inc.
Pasadena, California, United States
Pacific Research Network, Inc.
San Diego, California, United States
Affiliated Research Institute
San Diego, California, United States
...and 49 more locations